ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures
11 déc. 2024 08h00 HE
|
ProPhase Labs, Inc.
The Company will review on Thursday, December 12th, at 12:00 p.m. EST. GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a...
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024
13 nov. 2024 08h00 HE
|
ProPhase Labs, Inc.
Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a...
ProPhase Labs Announces Closing of Public Offering of Common Stock
12 nov. 2024 16h05 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the...
ProPhase Labs Announces Pricing of Public Offering of Common Stock
07 nov. 2024 23h37 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the...
ProPhase Labs Announces Proposed Public Offering of Common Stock
07 nov. 2024 16h05 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics and diagnostics company, today announced that it intends to offer to sell...
ProPhase Labs Launches DNA Complete®: Transforming Direct-to-Consumer Genetic Testing for Health, Wellness, and Enhanced Ancestry
04 nov. 2024 08h00 HE
|
ProPhase Labs, Inc.
Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:...
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025
17 oct. 2024 08h00 HE
|
ProPhase Labs, Inc.
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for BE-Smart Esophageal Cancer...
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event
19 août 2024 11h10 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced...
ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024
14 août 2024 08h00 HE
|
ProPhase Labs, Inc.
Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun in Q3 2024 and Potential Sale of Business ...
ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test
13 août 2024 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its collaboration with Forward...